<DOC>
	<DOCNO>NCT00990496</DOCNO>
	<brief_summary>The primary purpose study determine safety efficacy infusion partially match , allogeneic , CMV specific cytotoxic T cell ( CTL ) patient GBM fail primary therapy .</brief_summary>
	<brief_title>A Study Using Allogenic-Cytomegalovirus ( CMV ) Specific Cells Glioblastoma Multiforme ( GBM )</brief_title>
	<detailed_description>Tumor specimen consent patient test immunohistochemistry ( IHC ) presence IE-1 and/or pp65 . Subjects whose tumor test positive either CMV antigens consent treatment phase include regimen fludarabine cyclophosphamide daily two day , cyclophosphamide third day , follow one day rest prior day CTL infusion .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>FOR SCREENING Patients must histopathologic diagnosis GBM . Patients 5 65 year age GBM . FOR TREATMENT GBM progress follow primary therapy . Tumor CMV pp65 IE1 positive immunohistochemistry ( IHC ) . Subjects must pulse oximetry &gt; = 94 % supplemental oxygen . Creatinine clearance must &gt; 50 cc/min estimate patient 's serum creatinine , weight , age . Bilirubin must &lt; 2.0 mg/dl SGOT/SGPT &lt; 2.5 X normal . ECOG performance status must &lt; = 2 , patient &lt; 16 year age , Lansky performance status must &gt; = 70 % . Pregnant female Subjects moribund cardiac , pulmonary , renal , hepatic neurologic dysfunction expect survive one month follow T cell infusion</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Glioblastoma multiforme</keyword>
	<keyword>GBM</keyword>
	<keyword>Cytomegalovirus</keyword>
	<keyword>CMV</keyword>
	<keyword>Cytotoxic T lymphocyte</keyword>
	<keyword>CTL</keyword>
</DOC>